Zanubrutinib ( DrugBank: Zanubrutinib )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
300IgG4関連疾患1
331特発性多中心性キャッスルマン病1

300. IgG4関連疾患


臨床試験数 : 36 薬物数 : 49 - (DrugBank : 22) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 97
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04602598
(ClinicalTrials.gov)
January 15, 202220/10/2020Zanubrutinib in Patients With IgG4-Related DiseaseA Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients With IgG4-Related DiseaseIgG4 Related DiseaseDrug: Zanubrutinib 80 MGMatthew C. BakerStanford UniversityNot yet recruiting18 Years85 YearsAll10Phase 2United States

331. 特発性多中心性キャッスルマン病


臨床試験数 : 33 薬物数 : 46 - (DrugBank : 25) / 標的遺伝子数 : 31 - 標的パスウェイ数 : 155
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04743687
(ClinicalTrials.gov)
January 1, 20213/2/2021Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm TrialThe Efficacy and Safety of Zanuburutinib in Relapsed and Refractory Idiopathic Multicentric Castleman Disease (iMCD): a Prospective, Single-center, Single-arm TrialIdiopathic Multicentric Castleman's DiseaseDrug: ZanubrutinibPeking Union Medical College HospitalNULLRecruiting18 YearsN/AAll30Phase 2China